Efficacy of different methods used for dry socket prevention and risk factor analysis: A systematic review

Maria Taberner-Vallverdú 1, Mª Ángeles Sánchez-Garcés 2, Cosme Gay-Escoda 3

1 DDS. University of Barcelona, Barcelona (Spain)
2 MD, DDS, PhD, MS, EBOS, Associated professor of Oral Surgery. Master’s Degree Program in Oral Surgery and Implantology, School of Dentistry, University of Barcelona. Researcher at the IDIBELL institute, Barcelona (Spain)
3 MD, DDS, PhD, MS, EBOS, OMFS, Chairman and Professor of Oral and Maxillofacial Surgery, School of Dentistry, Barcelona. Director of the Master’s Degree Program in Oral Surgery and Implantology (EHFRE International University/ FUCSO). Coordinator/Researcher of the IDIBELL Institute. Head of the Oral Surgery, Implantology and Maxillofacial Surgery Department of the Teknon Medical Center, Barcelona (Spain)

Correspondence:
Centro Médico Teknon
C/Vilana 12
08022 Barcelona, Spain
cgay@ub.edu

Received: 29/10/2016
Accepted: 21/06/2017

Abstract
Background: Dry socket is one of the most common complications that develops after the extraction of a permanent tooth, and its prevention is more effective than its treatment.

Objectives: Analyze the efficacy of different methods used in preventing dry socket in order to decrease its incidence after tooth extraction.

Material and Methods: A Cochrane and PubMed-MEDLINE database search was conducted with the search terms “dry socket”, “prevention”, “risk factors”, “alveolar osteitis” and “fibrynolitic alveolitis”, both individually and using the Boolean operator “AND”. The inclusion criteria were: clinical studies including at least 30 patients, articles published from 2005 to 2015 and written in English. The exclusion criteria were case reports and non-human studies.

Results: 30 publications were selected from a total of 250. Six of the 30 were excluded after reading the full text. The final review included 24 articles: 9 prospective studies, 2 retrospective studies and 13 clinical trials. They were stratified according to their level of scientific evidence using SIGN criteria (Scottish Intercollegiate Guidelines Network).

Conclusions: All treatments included in the review were aimed at decreasing the incidence of dry socket. Locally administering chlorhexidine or applying platelet-rich plasma reduces the likelihood of developing this complication. Antibiotic prescription does not avoid postoperative complications after lower third molar surgery. With regard to risk factors, all of the articles selected suggest that patient age, history of previous infection and the difficulty of the extraction are the most common predisposing factors for developing dry socket. There is no consensus that smoking, gender or menstrual cycles are risk factors.

Taking the scientific quality of the articles evaluated into account, a level B recommendation has been given for the proposed-procedures in the prevention of dry socket.

Key words: Dry socket, prevention, alveolar osteitis, risk factors.
Introduction
Dry socket is the most common complication following tooth extraction (1) and one of the most studied complications in dentistry (2). There are up to 17 different definitions for the clinical diagnosis of dry socket (3). Blum (4) described dry socket as the presence of “postoperative pain in and around the extraction site, which increases in severity at any time between one and three days after the extraction, accompanied by a partially or totally disintegrated blood clot within the alveolar socket, with or without halitosis” (4) excluding any other cause of pain on the same side of the face. Its incidence is approximately 3% for all routine extractions and can exceed 30% for impacted mandibular third molars (5), and many factors have been cited as contributing to the occurrence of dry socket including difficult or traumatic extractions, female gender, tobacco use, oral contraceptive use and pre-existing infections (6). It has been suggested that increased local fibrinolytic activity is the main etiologic factor in developing dry socket. Increased in fibrinolytic activity could result in the premature loss of the intraalveolar blood clot after extraction (7). The fibrinolysis is the result of plasminogen pathway activation, which can be achieved via direct (physiologic) or indirect (nonphysiologic) activator substances. Direct activators are released after trauma to the alveolar bone cells. Indirect activators are secreted by bacteria (8). Apart from its role in the fibrinolytic process, the exact etiology of dry socket is not well understood (9, 10).

The treatment of alveolitis depends on each profession’s clinical experience (11) primarily due to its complex etiology, although substantial research has been published on the management of dry socket.
The Cochrane Collaboration published a review on local procedures for managing dry socket, and concluded there was no evidence to support any of the procedures should be included in its treatment (12). The aim of this systematic review is to analyze the different methods used for preventing dry socket. The following question emerged: what is the most effective method for preventing dry socket and reducing its incidence? In addition, would identifying the risk factors for dry socket reduce its incidence?

Material and Methods
A Cochrane and PubMed-MEDLINE databases search of articles was conducted between May 2015 and December 2015. The key words “dry socket”, “risk factors”, “alveolar osteitis” and “fibrinolitic alveolitis” were used. After that, the terms were combined using the Boolean operator “AND”, in order to obtain the articles that included two or more of the words used in the search.
The inclusion criteria were clinical studies that included at least 30 patients published from 2005 to 2015 and written in English. The exclusion criteria were case reports and nonhuman studies.

Articles were selected by one of the authors first reading the titles and abstracts and then reading the full text of the articles that met the inclusion criteria (Fig. 1). The PRISMA guideline for systematic reviews was followed during the process of selection of the articles, and these were assessed using the Cochrane Collaboration’s tool for assessing risk of bias.

Results
The complete texts of 30 articles were analyzed out of the 250 studies initially obtained from the search. Six of these 30 articles were excluded because they had no direct relationship with the subject and 24 relevant articles were finally selected to be included in our systematic review: 9 prospective studies, 2 retrospective studies and 13 clinical trials (Fig. 1).
The articles were stratified according to their level of evidence, using SIGN criteria (Scottish Intercollegiate Guidelines Network) (13) (Tables 1, 2), with a result of 9 articles with a 2+ scientific evidence level and 15 with a 2- scientific evidence level. According to the Cochrane assessment tool, the 9 articles had a low risk of bias and the other 15 articles had an unclear risk of bias.
The articles we reviewed analyzed three different methods for preventing dry socket: chlorhexidine (14-23), antibiotic therapy (24-31) and platelet-rich plasma (32,33). There were also some articles which analyzed other methods that were also included in the review (34-37). All these results can be seen on Table 3, 3 continue.

The concentration and formulation of chlorhexidine in
Grades of recommendation | Interpretation
--- | ---
A | At least one meta-analysis, randomized study or clinical study classified as 1+++ and directly applicable to the target population in the guide; or a volume of scientific evidence including studies rated as 1+ and with great consistency among them
B | A body of evidence including studies rated as 2++, directly applicable to the target population of the guide and demonstrating great consistency between them; or extrapolated evidence from studies rated as 1++ or 1+
C | A body of evidence including studies rated at 2+ directly applicable to the target population of the guide and demonstrating great consistency among them; or extrapolated evidence from studies rated as 2++
D | Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+

Table 1. SIGN Criteria (Scottish Intercollegiate Guidelines Network) (13).

| Level of evidence | Diagnosis |
|---|---|
| 1++ | High quality meta-analysis, high quality randomized studies or clinical studies with very low risk of bias |
| 1+ | Well performed meta-analysis, well performed randomized studies or clinical studies with little risk of bias |
| 1- | Meta-analysis, randomized study or clinical study with high risk of bias |
| 2++ | High quality randomized studies, case control or cohort studies. Cohort studies or case-control studies with very low risk of bias and with a high probability of establishing a causal relationship |
| 2+ | Well-performed cohort or case-control studies with low risk of bias and a moderate probability of establishing a causal relationship |
| 2- | Cohort or case-control studies at high risk of bias and significant risk that the relationship is not causal |
| 3 | Non-analytical studies, such as case reports and case series |
| 4 | Expert opinion |

Studies classified as 1- and 2- should not be used in the process of developing recommendations for its high potential for bias.
### Table 3. Different methods in the prevention of dry socket.

| Article                                | Level of scientific evidence | Number of cases | Procedure                          | Results (dry socket incidence) % |
|----------------------------------------|-----------------------------|-----------------|------------------------------------|----------------------------------|
| **CLORHEXIDINE**                       |                             |                 |                                    |                                  |
| Freudenthal et al. 2015 (16)           | 2+                          | 95              | GROUP 1 (control) n = 47           | 19                               |
|                                       |                             |                 | Placebo gel                        |                                  |
|                                       |                             |                 | GROUP 2 n = 48                     | 23                               |
|                                       |                             |                 | CHX gel 0.2%                       |                                  |
| Rubio-Palau et al. 2015 (17)           | 2+                          | 160             | GROUP 1 (control) n = 80           | 17.5                             |
|                                       |                             |                 | Placebo gel                        |                                  |
|                                       |                             |                 | GROUP 2 n = 80                     | 22.5                             |
|                                       |                             |                 | CHX gel 0.2%                       |                                  |
| Jesudasan et al. 2015 (23)             | 2+                          | 270             | GROUP 1 (control) n = 90           | 10                               |
|                                       |                             |                 | Placebo gel                        |                                  |
|                                       |                             |                 | GROUP 2 n = 90                     | 2.2                              |
|                                       |                             |                 | CHX gel 0.2%                       |                                  |
|                                       |                             |                 | GROUP 3 n = 90                     | 0                                |
|                                       |                             |                 | Eugenol paste                      |                                  |
| Rodríguez-Pérez et al. 2013 (15)      | 2-                          | 88              | GROUP 1 n = 46                     | 13                               |
|                                       |                             |                 | CHX gel 0.2%                       |                                  |
|                                       |                             |                 | GROUP 2 n = 42                     | 7                                |
|                                       |                             |                 | CHX gel 1%                         |                                  |
| Hita-Iglesias et al., 2008 (14)        | 2-                          | 73              | GROUP 1 n = 41                     | 7.5                              |
|                                       |                             |                 | CHX gel 0.2%                       |                                  |
|                                       |                             |                 | GROUP 2 n = 32                     | 25                               |
|                                       |                             |                 | CHX mouthwash 0.12%                |                                  |
| Sridhar et al., 2011 (22)             | 2-                          | 100             | GROUP 1 (control) n = 50           | 8                                |
|                                       |                             |                 | CHX mouthwash 0.2%                 |                                  |
| Torres-Lagares et al., 2006 (18)      | 2-                          | 30              | GROUP 1 (control) n = 13           | 30.7                             |
|                                       |                             |                 | CHX Gel 0.2%                       | 17.6                             |
| Torres-Lagares et al., 2006 (20)      | 2+                          | 103             | GROUP 1 (control) n = 50           | 11                               |
|                                       |                             |                 | Placebo gel                        |                                  |
|                                       |                             |                 | GROUP 2 n = 53                     | 30                               |
|                                       |                             |                 | CHX gel 0.2%                       |                                  |
| Torres-Lagares et al., 2010 (19)      | 2+                          | 38              | GROUP 1 (control) n = 24           | 17                               |
|                                       |                             |                 | CHX gel 0.2%                       |                                  |
| Haraji and Rakhshan 2015 (21)          | 2+                          | 90              | GROUP 1 (control) n = 45           | 17.8                             |
|                                       |                             |                 | CHX gel 0.2%                       | 6.7                              |
| **ANTIBIOTICS**                        |                             |                 |                                    |                                  |
| Bortoluzzi et al., 2013 (24)          | 2+                          | 50              | GROUP 1 (control) n = 12           | 8.3                              |
|                                       |                             |                 |                                    |                                  |
|                                       |                             |                 | GROUP 2 n = 12                     |                                  |
|                                       |                             |                 | Amoxicillin 2 mg                   | 0                                |
|                                       |                             |                 | Dexamethasone 8 mg                 |                                  |
|                                       |                             |                 | GROUP 3 n = 14                     |                                  |
|                                       |                             |                 | Amoxicillin 2 mg                   | 8.3                              |
|                                       |                             |                 | Placebo 8 mg                       |                                  |
|                                       |                             |                 | GROUP 4 n = 12                     |                                  |
|                                       |                             |                 | Placebo 2 mg                       | 0                                |
|                                       |                             |                 | Dexamethasone 8 mg                 |                                  |
### Table 3 continue. Different methods in the prevention of dry socket.

| Article                        | Level of scientific evidence | Number of cases | Procedure                                                                 | Results (dry socket incidence) % |
|--------------------------------|------------------------------|-----------------|---------------------------------------------------------------------------|----------------------------------|
| Lee et al. 2014 (25)           | 2-                           | 1222            | GROUP 1 (control) n = 783                                                  | 1                                |
|                                |                              |                 | GROUP 2 n = 439 Cefditoren pivoxil 100 mg                                  | 0.7                              |
| Halpern and Dodson 2007 (31)   | 2+                           | 118             | GROUP 1 (control) n = 59 Placebo                                           | 0                                |
|                                |                              |                 | GROUP 2 n = 59 Penicillin (15,000 units per kilogram)                       | 0                                |
| Xue et al. 2015 (26)           | 2+                           | 414             | GROUP 1 (control) n = 207 Amoxicillin 500 mg                               | 3                                |
|                                |                              |                 | GROUP 2 n = 207 Placebo                                                   | 2                                |
| Bezerra et al. 2011 (27)       | 2+                           | 136             | GROUP 1 (control) n = 68 Placebo                                          | 1.5                              |
|                                |                              |                 | GROUP 2 n = 68 Amoxicillin 500 mg                                          | 1.5                              |
| Kaczmaryck et al. 2007 (28)    | 2+                           | 86              | GROUP 1 (control) n = 27 Placebo                                           | 14.8                             |
|                                |                              |                 | GROUP 2 n = 31 Clindamycin 600 mg + Placebo for 5 days                     | 7.1                              |
|                                |                              |                 | GROUP 3 n = 28 Clindamycin 600 mg + 300 mg for 5 days                      | 14.8                             |
| Sanchis et al. 2004 (29)       | 2+                           | 200             | GROUP 1 (control) n = 100 Tetracycline 9 mg                                | 1                                |
|                                |                              |                 | GROUP 2 n = 100 Placebo                                                   | 3                                |
| Reekie et al. 2005 (30)        | 2+                           | 302             | GROUP 1 (control) n = 150 Gel placebo                                      | 1                                |
|                                |                              |                 | GROUP 2 n = 152 Metronidazole gel 25%                                      | 5.3                              |
| **PLATELET-RICH PLASMA**       |                              |                 |                                                                           |                                  |
| Eshghpour et al. 2013 (39)     | 2+                           | 156             | GROUP 1 (control) n = 78 Platelet-rich plasma                              | 12.5                             |
|                                |                              |                 | GROUP 2 n = 78 Platelet-rich plasma                                        | 5.5                              |
| Rutkowski et al. 2007 (33)     | 2+                           | 904             | GROUP 1 (control) n = 491 Platelet-rich plasma                             | 9.6                              |
|                                |                              |                 | GROUP 2 n = 413 Platelet-rich plasma                                       | 3.6                              |
| **OTHER METHODS**              |                              |                 |                                                                           |                                  |
| Osunde et al. 2014 (34)        | 2-                           | 120             | GROUP 1 (control) n = 80 Warm saline mouth rinse                           | 25                               |
|                                |                              |                 | GROUP 2 n = 40 Absorbable type I collagen sponge                           | 2.5                              |
| Cho et al. 2015 (35)           | 2-                           | 3869            | GROUP 1 (control) n = 50 Topical hemostatic agent                          | 14                               |
|                                |                              |                 | GROUP 2 n = 50 Topical hemostatic agent                                    | 16                               |
| Tek et al. 2014 (36)           | 2-                           | 100             | GROUP 1 (control) n = 35 Immediate post-extraction Intervention            | 77.8                             |
|                                |                              |                 | GROUP 2 n = 35 Non-irrigation                                              | 22.2                             |

---

**Note:** The results are based on the dry socket incidence reported in each study. The level of scientific evidence is indicated by the following grades: 2+ for high evidence, 2- for moderate evidence, and 3 for low evidence. The number of cases and the procedure used in each study are also provided.
preventing dry socket used 0.12%, 0.2% and 1% gel formulation (15-21,23) or 0.2% chlorhexidine mouthwash (22) in the articles reviewed. In only one article (14) was a comparison made between the two formulations. The results obtained are rather contradictory, because the gel group showed a major decrease in dry socket incidence in the last article (14), but the mouthwash formulation showed better results in all the other articles (21).

The antibiotic used, the dosage and the route of administration were also different in each article which analyzed the efficacy of this method for preventing dry socket, this being prescribing amoxicillin (or clindamycin in the case of allergy to penicillin) one of the most studied medications, in 500 mg or 2 g doses. Bortoluzzi et al. (24) studied the synergic effect of amoxicillin with dexamethasone. The other antibiotics studied were cefitoren pivoxil (a third-generation oral cephalosporin) (25), tetracycline (29) and topical metronidazole (30).

It must be noted that the articles described third molar extractions except Reekie et al. (30), who also included premolar extractions in their sample.

With regard to the risk factor identification, 9 articles specifically dealt with the major risk factors for dry socket; all of the articles were prospective studies. Five articles (38-42) analyzed risk factors after third molar extractions, while four articles (43-46) did so after either surgical or non-surgical extractions. Therefore, this is a representative sample for dry socket after all types of extractions.

Risk factors such as previous surgical infection (37), the reason for extraction (44-45), tobacco use (38,43-44), anesthesia, the amount of anesthesia (38), menstrual cycles (38), older patient age (41), surgical difficulty (41,43,44) and some drugs (45) were associated with an increased risk of alveolar osteitis. However, the patient’s gender wasn’t considered to be a risk (40).

Discussion

- Dry socket prevention

After analyzing chlorhexidine’s efficacy as a way of preventing dry socket, the ten articles included in this review didn’t come to any conclusive results. Five of these articles suggested that applying chlorhexidine after the extraction to the alveoli did not yield better results than the control group, although one article did find significant differences (21). Mouthwash (22) used pre and post extraction did show a significant decrease in dry socket incidence. Nevertheless, a comparative study between the two formulations (15) obtained better results for the gel group. This results agree with Mínguez-Serra’s et al. review (47), and as the authors themselves point out, mouthwash is a more economical alternative and therefore perhaps more recomendable in public health systems.

In addition, when comparing chlorhexidine (in gel formulation) with another preventive method like eugenol (Alvogyl®) (23), the latter showed better results not only decreasing pain and inflammation, but also by promoting alveolar mucosa healing.

With respect to antibiotic prescription, there is a consensus between the eight articles included in the review. Seven of them conclude that the prophylactic regimen is unnecessary, since it does not prevent dry socket. Even so, Halpern and Dodson (31) do describe the beneficial effects of intravenous penicillin prescription thereby reducing postoperative inflammatory complications, but not on dry socket in particular. In their meta-analysis, Ren et al. (48) conclude that there is a reduction in dry socket incidence when an antibiotic prescription is performed preoperatively, but they express their doubts about the risk/benefit ratio; in order to avoid 1 case of dry socket, 13 patients have to take antibiotics, thereby increasing resistance and the other drawbacks it entails. It is still a very controversial issue.

Platelet-rich plasma may also have a preventive effect as well as being efficient in dry socket management (11). The two articles included in the review (32-33) show significant differences in dry socket incidence with respect to the control group. However, as Barona-Dorado et al. (49) points out in their systematic review, more randomized clinical trials are needed before suggesting this method.

In relation to the other methods described for dry socket prevention, the results were diverse. Both warm saline mouth rinse (34) and absorbable collagen sponges (35) showed significant results, as well as immediate post-extraction socket irrigation. The topical hemorrhagic agent, Ankafer Blood Stopper (ABS; Ankaferd Health Products Ltd., Istanbul, Turkey) (36), a traditional medicinal plant extract product used as a hemostatic agent, didn’t achieve better results than the control group.

- Risk factors

Regarding dry socket risk factors, Chuang et al. (40) makes a distinction between modifiable and non-modifiable risk factors. Despite the importance of their identification, most of them cannot be modified by the clinician.

These authors point out that the only modifiable factor is the pre-surgical infection site that could be inoculated with microorganisms from the external environment in the newly exposed socket after extraction (43). Partharsarathi et al. (46) goes on to explain in their article that periodontal extractions have an odds ratio of 7.5 for developing dry socket. This fact could be related to all pathogens involved in dry socket etiology.

Another modifiable factor may be tobacco use, even though there is no clear data indicating a higher predisposition in smoking patients. Three articles (38, 43, 45) describe a greater incidence in smokers, especially in the 24 hours following the extraction, but neither Haraji...
or Rakhshan (42) and Parhasarathi et al. (46) found significant results, the latter pointing out an inadequate statistical analysis as the cause of this misconception. In fact, the pathway that links tobacco to dry socket is still unknown, the predominant theory suggesting that mechanical clot dislodgement occurs with the sucking motion in smoking (46), although the formation of granulation tissue or a decreased local immune and inflammatory response (43) may also play a role.

Only Eshghpour and Nejat (38) describe the amount of anesthesia used during the extraction as a possible risk factor. They explain that epinephrine might attenuate healing by reducing bleeding and oxygen tension and also increases fibrinolysis. They also observed that the number of cartridges used in local anesthesia was determining factor in dry socket incidence and there was a higher incidence when three cartridges were used (38). With respect to the menstrual cycles and oral contraceptive use, Eshghpour et al. (39) found a decreased incidence of dry socket in those patients who underwent the extraction during their menstrual periods and a higher incidence in those who consumed oral contraceptives and underwent the extraction in the middle of their menstrual cycles, due to increased fibrinolytic activity produced by the drug. These authors describe an increase in dry socket incidence since the introduction of oral contraceptives in the 1960s. Nonetheless, Parhasarathi et al. (46) did not find any differences when contraceptives were used. This difference may be attributed to the lower amount of estrogen present in current oral contraceptives (50).

Abu Younis et al. (45) believes that single tooth extractions have a higher risk factor as compared to multiple extractions since the second procedure is performed when there is periodontal disease and is therefore a simpler procedure. The results of four other articles included in the review (42-45) support the relationship between elevated surgical difficulty and dry socket, since trauma favors delayed healing through compression of the bony lining of the socket, thrombosis in underlying vessels, reduced tissue resistance, and predisposes the wound to infection (44). Parhasarathi et al. (46) also points out this out as the reason for the higher incidence of dry socket in posterior teeth, although it is less prevalent in mandibular teeth in contrast to what Oginni states in his article (44).

Professional experience was only analyzed in one article (46), showing a higher incidence in those surgeries carried out by specialists, but as the authors themselves point out the results seem to be biased due to the greater difficulty involved in these extractions. Parhasarathi et al. (46) were the only ones who found a higher incidence of dry socket in patients taking antipsychotic and antidepressant drugs (OR 5.9), possibly due to the drug-induced hyposalivation that may reduce salivary protective components.

Only Oginni (44) states the importance of insisting on good oral health in order to reduce incidence of dry socket.

Finally, with reference to age and gender as risk factors, all of the authors except Eshghpour and Nejat (38) described an increase of dry socket incidence with age, with an increased likelihood of 1.9 times per year, according to Haraji and Rakhshan (42). This fact can be attributed to a slower metabolism, worse healing and a weaker immune system (42). Only Malkawi et al. (41) found a higher incidence in men although the rest of the articles did not find significant differences with regard to the patient’s gender.

Some limitations encountered during the review process were the lack of consensus in the preventive methods used in the articles included in the review, being the formulation and dosage of the method studied different in each article, and therefore their comparison was quite challenging. Also, the diversity of the risk factors considered in the articles included made it difficult to compare all the studies with accuracy.

Conclusions

Chlorhexidine administration or platelet rich plasma reduce dry socket development. Antibiotic prescriptions do not have a preventive effect on postoperative inflammatory complications.

Age, history of previous infection and difficulty of extraction are risk factors for developing dry socket and should therefore be taken into account by the clinician when carrying out the procedure. There is no consensus that tobacco use and menstrual cycles play a role in the development of dry socket.

After the article’s analysis and according to their scientific quality, a level C recommendation is given to all the therapeutic procedures proposed for preventing dry socket.

References

11. Burgoyne CC, Giglio JA, Reese SE, Sima AP, Laskin DM. The efficacy of a topical anesthetic gel in the relief of pain associated with localized alveolar osteitis. J Oral Maxillofac Surg. 2010;68:144-8.
2. Cardoso CL, Rodrigues MTV, Ferreira Júnior O, Garlet GP, de Carvalho PSP. Clinical concepts of dry socket. J Oral Maxillofac Surg. 2010;68:1922-32.
3. Torres-Lagares D, Serrera-Figallo MA, Romero-Ruiz MM, Infante-Cossío P, García-Calderón M, Gutiérrez-Pérez JL. Update on dry socket: A review of the literature. Med Oral Patol Oral Cir Bucal. 2005;10:77-85.
4. Blum IR. Contemporary views on dry socket (alveolar osteitis): A critical review. Int J Oral Maxillofac Surg. 2002;31:309-17.
5. Bowe DC, Rogers S, Stassen LFA. The management of dry socket/ alveolar osteitis. J Ir Dent Assoc. 2011;57:305-10.
6. Nusair YM, Goussous ZM. Quantifying the healing of dry socket. J Oral Maxillofac Surg. 2010;68:1922-32.
7. Noroozi A-R, Philipsert RF. Modern concepts in understanding and management of the “dry socket” syndrome: Comprehensive review.
of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:30-5.

8. Kolokythas A, Olech E, Miloro M. Alveolar osteitis: A comprehensive review of concepts and controversies. Int J Dent. 2010;2010:249073.

9. Cardoso CL, Ferreira Júnior O, Carvalho PS, Dionísio TJ, Cestari TM, Garlet GP. Experimental dry socket. Acta Cir Bras. 2011;26:365-72.

10. de Carvalho PS, Mariano RC, Okamoto T. Treatment of fibrinolytic alveolitis. Braz Dent J. 1997;8:3-8.

11. Taberner-Valverda M, Nazir M, Sánchez-Garcés MA, Gay-Esco- da C. Efficacy of different methods used for dry socket management: A systematic review. Med Oral Patol Oral Cir Bucal. 2015;20:633-9.

12. Daly B, Sharif MO, Newton T, Jones K, Worthington H V. Local interventions for the management of alveolar osteitis (dry socket). Cochrane database Syst Rev 2012; 12:CD006968.

13. Scottish Intercollegiate Guidelines Networks. SIGN 50: A guideline developer’s handbook. Edinburgh: SIGN; 2001.

14. Hita-Iglesias P, Torres-Lagares D, Flores-Ruíz R, Magallanes-Abad N, Basallote-González M, Gutiérrez-Pérez JL. Effectiveness of chlorhexidine gel versus chlorhexidine rinse in reducing alveolar osteitis in mandibular third molar surgery. J Oral Maxillofac Surg. 2008;66:441-5.

15. Rodríguez-Pérez M, Bravo-Pérez M, Sánchez-López JD, Muñoz-Soto E, Romero-Ólido MN, Baca-García P. Effectiveness of 1% versus 0.2% chlorhexidine gels in reducing alveolar osteitis from mandibular third molar surgery: A randomized, double-blind clinical trial. Med Oral Patol Oral Cir Bucal. 2013;18:693-700.

16. Freudenthal N, Sternaud M, Janssens L, Wannateurs K. A double-blind randomized study evaluating the effect of intra-alveolar chlorhexidine gel on alveolar osteitis after removal of mandibular third molars. J Oral Maxillofac Surg. 2015;73:600-5.

17. Rubio-Palau J, García-Linares J, Hueto-Madrid JA, González-Lagunas J, Raspall-Martín G, Mareque-Bueno J. Effect of intra-alveolar placement of 0.2% chlorhexidine bioadhesive gel on the incidence of alveolar osteitis following the extraction of mandibular third molars. A double-blind randomized clinical trial. Med Pat Oral Cir Bucal. 2015;20:177-22.

18. Torres-Lagares D, Infante-Cossio P, Gutiérrez-Pérez JL, Romero-Ruíz MM, García-Calderón M, Serrera-Figallo MA. Intra-alveolar chlorhexidine gel for the prevention of dry socket in mandibular third molar surgery. A pilot study. Med Oral Patol Oral Cir Bucal. 2006;11:e179-84.

19. Torres-Lagares D, Gutiérrez-Pérez JL, Hita-Iglesias P, Magallanes-Abad N, Flores-Ruíz R, Basallote-García M, González-Martin M. Randomized, double-blind study of effectiveness of intra-alveolar application of chlorhexidine gel in reducing incidence of alveolar osteitis and bleeding complications in mandibular third molar surgery in patients with bleeding disorders. J Oral Maxillofac Surg. 2010;68:1322-6.

20. Torres-Lagares D, Gutiérrez-Pérez JL, Infante-Cossio P, García-Calderón M, Romero-Ruíz MM, Serrera-Figallo MA. Randomized, double-blind study on effectiveness of intra-alveolar chlorhexidine gel in reducing the incidence of alveolar osteitis in mandibular third molar surgery. Int J Oral Maxillofac Surg. 2006;35:348-51.

21. Haraji A, Rakhshan V. Clorhexidine gel and less difficult surgery might reduce post-operative pain, controlling for dry socket and inflammatory complications after mandibular third molar removal: A prospective split-mouth, double-blind, self-controlled, clinical trial. Br J Oral Maxillofac Surg. 2015;53:416-20.

22. Bezerra TP, Studart-Soares EC, Scaparo HC, Pita-Neto IC, Batista SH, Fontes CS. Prophylaxis versus placebo treatment for infective and inflammatory complications of surgical third molar removal: A split-mouth, double-blind, controlled clinical trial with amoxicillin (500 mg). J Oral Maxillofac Surg. 2011;69:333-9.

23. Vazquez SY, Wielinski JS, Stypulkowska J, Zaleska M, Panas M, Woron J. Single-dose and multi-dose clindamycin therapy fails to demonstrate efficacy in preventing infectious and inflammatory complications in third molar surgery. Int J Oral Maxillofac Surg. 2007;36:417-22.

24. Sanghavi J, Sáez U, Pe-arrocha M, Gay-Escoda C. Tetracycline compound placement to prevent dry socket: A prospective study of 200 impacted mandibular third molars. J Oral Maxillofac Surg. 2004;62:587-91.

25. Lee JY, Do HS, Lim JH, Jang HS, Rim JS, Kwon JJ, Lee ES. Correlation of antibiotic prophylaxis and difficulty of extraction with postoperative inflammatory complications in the lower third molar surgery. Br J Oral Maxillofac Surg. 2014;52:54-7.

26. Xue P, Wang J, Wu B, Ma Y, Wu F, Hou R. Efficacy of anti-biotic prophylaxis on postoperative inflammatory complications in Chinese patients having impacted mandibular third molars removed: A split-mouth, double-blind, self-controlled, clinical trial. Br J Oral Maxillofac Surg. 2015;53:416-20.

27. Dall'Asta SH, Fonteles CS. Prophylaxis versus placebo treatment for infective and inflammatory complications of surgical third molar removal: A split-mouth, double-blind, controlled clinical trial with amoxicillin (500 mg). J Oral Maxillofac Surg. 2011;69:333-9.

28. Kasznarik T, Wichlinski J, Stypulkowska J, Zaleska M, Panas M, Woron J. Single-dose and multi-dose clindamycin therapy fails to demonstrate efficacy in preventing infectious and inflammatory complications in third molar surgery. Int J Oral Maxillofac Surg. 2007;36:417-22.

29. Sanchis JM, à Sze U, Pe-arrocha M, Gay-Escoda C. Tetracycline compound placement to prevent dry socket: A prospective study of 200 impacted mandibular third molars. J Oral Maxillofac Surg. 2004;62:587-91.

30. Reekie D, Downes P, Devlin CV, Nixon GM, Devlin H. The pre-vention of “dry socket” with topical metronidazole in general dental practice. Br Dent J. 2006;200:337-41.

31. Halpern LR, Dodson TB. Does prophylactic administration of systemic antibiotics prevent postoperative inflammatory complications after third molar surgery? J Oral Maxillofac Surg. 2007;65:177-85.

32. Eshghpour M, Dastmalchi P, Nekooei AH, Nejat A. Effect of platelet-rich fibrin on frequency of alveolar osteitis following mandibular third molar surgery: A double-blinded randomized clinical trial. J Oral Maxillofac Surg. 2014;72:1463-7.

33. Rutkowski JL, Fennell JW, Kern JC, Madison DE, Johnson DA. Inhibition of alveolar osteitis in mandibular tooth extraction sites using platelet-rich plasma. J Oral Implantol. 2007;33:116-21.

34. Osunde OD, Adebola RA, Adebeye JB, Bassey GO. Comparative study of the effect of warm saline mouth rinse on complications after dental extractions. Int J Oral Maxillofac Surg. 2014;43:649-53.

35. Cho H, Jung HD, Kim BJ, Kim CH, Jung YS. Complication rates in patients using absorbable collagen sponges in third molar extraction sockets: A retrospective study. J Korean Assoc Oral Maxillofac Surg. 2015;41:26-9.

36. Tek M, Akkas I, Toptas O, Ozan F, Sener I, Bereket C. Effects of the topical hemostatic agent Ankaferd Blood Stopper on the incidence of alveolar osteitis after surgical removal of an impacted mandibular third molar. Niger J Clin Pract. 2014;17:75-80.

37. Tolstunov L. Influence of immediate post-extraction socket irrigation on development of alveolar osteitis after mandibular third molar removal: A prospective split-mouth study, preliminary report. Br Dent J. 2012;213:597-601.

38. Eshghpour M, Nejat AH. Dry socket following surgical removal of impacted third molars in an Iranian population. Incidence and risk factors. Niger J Clin Pract. 2013;16:496-500.

39. Eshghpour M, Rezaei NM, Nejat A. Effect of menstrual cycle on frequency of alveolar osteitis following mandibular third molar surgery: A double-blind randomized clinical trial. J Oral Maxillofac Surg. 2014;72:1463-7.

40. Chua CH, Perrott DH, Susarla SM, Dodson TB. Risk factors for inflammatory complications following third molar surgery in adults. J Oral Maxillofac Surg. 2006;66:2213-8.

41. Malikawi Z, Al-Omier MK, Khraisat A. Risk indicators of post-operative complications following surgical extraction of lower third molars. Med Princ Pract. 2011;20:321-5.
gel application, easier surgeries, and younger ages are associated with reduced dry socket risk. J Oral Maxillofac Surg. 2014;72:259-65.

43. Halabi D, Escobar J, Muo-oz C, Uribe S. Logistic regression analysis of risk factors for the development of alveolar osteitis. J Oral Maxillofac Surg. 2012;70:1040-4.

44. Oginni FO. Dry socket: A prospective study of prevalent risk factors in a Nigerian population. J Oral Maxillofac Surg. 2008;66:2290-5.

45. Abu Younis MH, Abu Hantash RO. Dry socket: Frequency, clinical picture, and risk factors in a palestinian dental teaching center. Open Dent J. 2011;5:7-12.

46. Parthasarathi K, Smith A, Chandu A. Factors affecting incidence of dry socket: A prospective community-based study. J Oral Maxillofac Surg. 2011;69:1880-4.

47. Minguez-Serra MP, Salort-Llorca C, Silvestre-Donat FJ. Chlorhexidine in the prevention of dry socket: Effectiveness of different dosage forms and regimens. Med Oral Patol Oral Cir Bucal. 2009;14:e445-9.

48. Ren YF, Malmstrom HS. Effectiveness of antibiotic prophylaxis in third molar surgery: A meta-analysis of randomized controlled clinical trials. J Oral Maxillofac Surg. 2007;65:1909-21.

49. Barona-Dorado C, González-Regularo I, Martín-Ares M, Arias-Irimia O, Martínez-González JM. Efficacy of platelet-rich plasma applied to post-extraction retained lower third molar alveoli. A systematic review. Med Oral Patol Oral Cir Bucal. 2014;19:142-8.

50. Rakhshan V. Common risk factors for postoperative pain following the extraction of wisdom teeth. J Korean Assoc Oral Maxillofac Surg. 2015;41:59-65.

Acknowledgments
The authors declare no conflict of interest and no source of funding. This study was carried out by the research group “Odontological and Maxillofacial Pathology and Therapeutics” at the IDIBELL Institute.

Conflicts of interest
The authors of this paper have no conflict of interest in reporting this publication.